KYMR
Kymera Therapeutics, Inc. NASDAQ Listed Aug 21, 2020$84.66
After hrs
$86.08
+0.00%
Mkt Cap $7.0B
52w Low $28.06
75.5% of range
52w High $103.00
50d MA $84.14
200d MA $67.77
P/E (TTM)
-21.9x
EV/EBITDA
-20.8x
P/B
4.3x
Debt/Equity
0.1x
ROE
-19.7%
P/FCF
-28.0x
RSI (14)
—
ATR (14)
—
Beta
2.29
50d MA
$84.14
200d MA
$67.77
Avg Volume
694.4K
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
200 Arsenal Yards Boulevard · Watertown, MA 02472 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | BMO | -0.89 | -0.71 | +20.2% | 81.51 | +4.8% | -0.5% | -1.0% | +2.6% | +1.5% | +5.8% | — |
| Feb 26, 2026 | BMO | -0.78 | -0.97 | -23.8% | 90.68 | -5.2% | +4.8% | +0.7% | -0.6% | -4.8% | -5.0% | — |
| Nov 4, 2025 | BMO | -0.71 | -0.90 | -26.8% | 59.72 | -6.6% | +0.3% | +0.3% | +2.1% | -1.8% | +2.6% | — |
| Aug 11, 2025 | BMO | -0.83 | -0.95 | -14.5% | 40.62 | -6.1% | -7.2% | -1.8% | +0.3% | +2.3% | +4.9% | — |
| May 9, 2025 | BMO | -0.92 | -0.82 | +10.9% | 30.77 | +9.3% | -2.3% | +4.5% | +1.2% | -3.3% | -2.4% | — |
| Feb 27, 2025 | BMO | -0.76 | -0.88 | -15.8% | 35.36 | -3.8% | -14.5% | -11.3% | -14.7% | -13.2% | -10.4% | — |
| Oct 31, 2024 | BMO | -0.83 | -0.82 | +1.2% | 47.67 | -6.1% | -3.1% | -2.5% | -1.3% | +0.0% | +3.8% | — |
| Aug 7, 2024 | BMO | -0.69 | -0.58 | +15.9% | 41.42 | +9.8% | -2.7% | +1.4% | +0.0% | +2.6% | +3.8% | — |
| May 2, 2024 | BMO | -0.73 | -0.69 | +5.5% | 36.24 | -0.2% | +0.2% | +3.2% | +5.7% | +6.1% | +6.2% | — |
| Feb 22, 2024 | BMO | -0.44 | -0.25 | +43.2% | 38.67 | +2.9% | +4.7% | +8.2% | +12.3% | +12.7% | +11.8% | — |
| Nov 2, 2023 | BMO | -0.73 | -0.90 | -23.3% | 11.55 | -12.6% | +4.6% | +23.5% | +24.7% | +41.6% | +38.1% | — |
| Aug 3, 2023 | BMO | -0.70 | -0.67 | +4.3% | 21.50 | +9.3% | +11.1% | +5.0% | -6.6% | -7.4% | -7.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6 | Canaccord Genuity | Initiates | Buy | $106 | $82.71 | $84.08 | +1.7% | +4.3% | +2.3% | — | — | — |
| Mar 3 | UBS | Maintains | Buy → Buy | — | $90.10 | $87.41 | -3.0% | -4.2% | -4.4% | -7.3% | -7.3% | -5.6% |
| Mar 2 | Citigroup | Maintains | Buy → Buy | — | $91.35 | $89.24 | -2.3% | -1.4% | -5.5% | -5.7% | -8.6% | -8.6% |
| Mar 2 | Stephens & Co. | Maintains | Overweight → Overweight | — | $91.35 | $89.24 | -2.3% | -1.4% | -5.5% | -5.7% | -8.6% | -8.6% |
| Feb 26 | BTIG | Maintains | Buy → Buy | — | $90.68 | $86.00 | -5.2% | +4.8% | +0.7% | -0.6% | -4.8% | -5.0% |
| Feb 26 | Piper Sandler | Maintains | Overweight → Overweight | — | $90.68 | $86.00 | -5.2% | +4.8% | +0.7% | -0.6% | -4.8% | -5.0% |
| Feb 3 | BTIG | Maintains | Buy → Buy | — | $75.62 | $75.16 | -0.6% | +2.1% | +2.8% | +0.4% | +5.2% | +4.5% |
| Jan 28 | Barclays | Maintains | Overweight → Overweight | — | $72.15 | $72.54 | +0.5% | -1.4% | +2.4% | +0.7% | +4.8% | +7.0% |
| Jan 15 | BTIG | Maintains | Buy → Buy | — | $75.21 | $75.37 | +0.2% | -5.4% | -7.5% | -9.4% | -5.9% | -3.2% |
| Jan 6 | Wolfe Research | Downgrade | Outperform → Peer Perform | — | $72.41 | $70.66 | -2.4% | +1.5% | +5.9% | +3.5% | +3.3% | +0.9% |
| Dec 22 | B. Riley Securities | Maintains | Buy → Buy | — | $83.99 | $84.73 | +0.9% | +0.4% | -0.5% | -1.0% | -3.2% | -4.3% |
| Dec 16 | RBC Capital | Maintains | Outperform → Outperform | — | $85.68 | $86.32 | +0.7% | -1.7% | -4.2% | -7.1% | -2.0% | -1.6% |
| Dec 11 | Mizuho | Maintains | Outperform → Outperform | — | $89.89 | $90.74 | +0.9% | -2.3% | -0.2% | -4.7% | -6.3% | -8.7% |
| Dec 11 | Stephens & Co. | Maintains | Overweight → Overweight | — | $89.89 | $90.74 | +0.9% | -2.3% | -0.2% | -4.7% | -6.3% | -8.7% |
| Dec 10 | JP Morgan | Maintains | Overweight → Overweight | — | $86.88 | $93.07 | +7.1% | +3.5% | +1.1% | +3.2% | -1.4% | -3.1% |
| Dec 9 | Morgan Stanley | Maintains | Overweight → Overweight | — | $94.30 | $90.72 | -3.8% | -7.9% | -4.7% | -6.9% | -4.9% | -9.1% |
| Dec 9 | Barclays | Maintains | Overweight → Overweight | — | $94.30 | $90.72 | -3.8% | -7.9% | -4.7% | -6.9% | -4.9% | -9.1% |
| Dec 9 | Leerink Partners | Maintains | Outperform → Outperform | — | $94.30 | $90.72 | -3.8% | -7.9% | -4.7% | -6.9% | -4.9% | -9.1% |
| Dec 9 | Wells Fargo | Maintains | Overweight → Overweight | — | $94.30 | $90.72 | -3.8% | -7.9% | -4.7% | -6.9% | -4.9% | -9.1% |
| Dec 9 | BofA Securities | Maintains | Buy → Buy | — | $94.30 | $90.72 | -3.8% | -7.9% | -4.7% | -6.9% | -4.9% | -9.1% |
| Dec 9 | BTIG | Maintains | Buy → Buy | — | $94.30 | $90.72 | -3.8% | -7.9% | -4.7% | -6.9% | -4.9% | -9.1% |
| Dec 9 | Citigroup | Maintains | Buy → Buy | — | $94.30 | $90.72 | -3.8% | -7.9% | -4.7% | -6.9% | -4.9% | -9.1% |
| Dec 9 | Jefferies | Maintains | Buy → Buy | — | $94.30 | $90.72 | -3.8% | -7.9% | -4.7% | -6.9% | -4.9% | -9.1% |
| Dec 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $94.30 | $90.72 | -3.8% | -7.9% | -4.7% | -6.9% | -4.9% | -9.1% |
| Dec 9 | Oppenheimer | Maintains | Outperform → Outperform | — | $94.30 | $90.72 | -3.8% | -7.9% | -4.7% | -6.9% | -4.9% | -9.1% |
| Dec 9 | Truist | Maintains | Buy → Buy | — | $94.30 | $90.72 | -3.8% | -7.9% | -4.7% | -6.9% | -4.9% | -9.1% |
| Dec 9 | Piper Sandler | Maintains | Overweight → Overweight | — | $94.30 | $90.72 | -3.8% | -7.9% | -4.7% | -6.9% | -4.9% | -9.1% |
| Nov 26 | Truist | Maintains | Buy → Buy | — | $66.04 | $66.89 | +1.3% | +2.8% | +2.8% | +1.2% | -2.7% | -0.1% |
| Nov 5 | Barclays | Maintains | Overweight → Overweight | — | $59.91 | $59.07 | -1.4% | -0.0% | +1.8% | -2.1% | +2.3% | +5.8% |
| Nov 5 | Wells Fargo | Maintains | Overweight → Overweight | — | $59.91 | $59.07 | -1.4% | -0.0% | +1.8% | -2.1% | +2.3% | +5.8% |
| Nov 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $59.91 | $59.07 | -1.4% | -0.0% | +1.8% | -2.1% | +2.3% | +5.8% |
| Oct 22 | BTIG | Maintains | Buy → Buy | — | $58.32 | $59.19 | +1.5% | -4.3% | -1.0% | +0.4% | +4.3% | +6.2% |
| Oct 17 | Citigroup | Maintains | Buy → Buy | — | $60.46 | $60.20 | -0.4% | -1.0% | +0.1% | -3.5% | -7.7% | -4.5% |
| Oct 1 | Oppenheimer | Maintains | Outperform → Outperform | — | $56.60 | $56.30 | -0.5% | -3.4% | -1.1% | +2.3% | +1.7% | +0.6% |
| Sep 30 | Truist | Maintains | Buy → Buy | — | $58.50 | $58.93 | +0.7% | -3.2% | -6.6% | -4.3% | -1.0% | -1.6% |
| Sep 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $48.12 | $49.39 | +2.6% | +6.3% | +2.1% | +6.0% | +5.7% | +9.1% |
| Jun 27 | Oppenheimer | Maintains | Outperform → Outperform | — | $45.71 | $46.43 | +1.6% | -3.5% | -4.5% | -2.8% | -2.6% | -2.0% |
| Jun 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $46.47 | $45.51 | -2.1% | -1.6% | -5.1% | -6.1% | -4.4% | -4.2% |
| Jun 26 | Wells Fargo | Maintains | Overweight → Overweight | — | $46.47 | $45.51 | -2.1% | -1.6% | -5.1% | -6.1% | -4.4% | -4.2% |
| Jun 3 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | $43.13 | $44.95 | +4.2% | +1.0% | +2.6% | +10.5% | +10.4% | +9.3% |
| Jun 3 | B. Riley Securities | Upgrade | Neutral → Buy | — | $43.13 | $44.95 | +4.2% | +1.0% | +2.6% | +10.5% | +10.4% | +9.3% |
| Jun 3 | JP Morgan | Maintains | Overweight → Overweight | — | $43.13 | $44.95 | +4.2% | +1.0% | +2.6% | +10.5% | +10.4% | +9.3% |
| May 13 | UBS | Maintains | Buy → Buy | — | $32.17 | $32.30 | +0.4% | -3.2% | -7.5% | -6.7% | -6.0% | -6.1% |
| May 12 | Guggenheim | Maintains | Buy → Buy | — | $30.07 | $31.37 | +4.3% | +7.0% | +3.6% | -1.1% | -0.2% | +0.6% |
| May 12 | B. Riley Securities | Maintains | Neutral → Neutral | — | $30.07 | $31.37 | +4.3% | +7.0% | +3.6% | -1.1% | -0.2% | +0.6% |
| May 12 | BofA Securities | Maintains | Neutral → Neutral | — | $30.07 | $31.37 | +4.3% | +7.0% | +3.6% | -1.1% | -0.2% | +0.6% |
| May 12 | JP Morgan | Maintains | Overweight → Overweight | — | $30.07 | $31.37 | +4.3% | +7.0% | +3.6% | -1.1% | -0.2% | +0.6% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $30.25 | $30.20 | -0.2% | +3.6% | -0.3% | +1.4% | +4.8% | +7.6% |
| Jan 21 | Stephens & Co. | Maintains | Overweight → Overweight | — | $40.61 | $41.65 | +2.6% | +7.6% | +8.7% | +8.9% | +9.2% | +1.5% |
| Dec 27 | Leerink Partners | Maintains | Outperform → Outperform | — | $42.02 | $41.98 | -0.1% | -4.5% | -6.4% | -4.3% | -2.7% | -1.0% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2026 | Mainolfi Nello | Chief Executive Officer | Sell | 936 | $82.45 | $77K | 666,195 | -0.54% | +5.83% |
| Apr 29, 2026 | Mainolfi Nello | Chief Executive Officer | Sell | 12,059 | $81.70 | $985K | 667,131 | -0.54% | +5.83% |
| Apr 29, 2026 | Mainolfi Nello | Chief Executive Officer | Sell | 17,005 | $80.74 | $1.4M | 679,190 | -0.54% | +5.83% |
8-K
Kymera Therapeutics, Inc. -- 8-K Filing
Kymera Therapeutics (KYMR) reported Q1 2026 results while advancing its oral degrader candidates KT-621 and KT-579 through clinical development, targeting multiple pipeline milestones this year.
Apr 30
8-K
Unknown — 8-K Filing
I cannot provide meaningful analysis from this filing excerpt, as it contains only standard signature blocks without substantive disclosure of what material event triggered the 8-K filing.
Mar 27
8-K
Kymera Therapeutics, Inc. -- 8-K Filing
Kymera Therapeutics appointed veteran biopharma executive Neil Graham as Chief Development Officer while advancing multiple clinical programs, including KT-621 in atopic dermatitis and asthma with data readouts expected through 2027.
Feb 26
8-K
Kymera Therapeutics, Inc. -- 8-K Filing
Kymera Therapeutics established an at-the-market equity offering agreement with TD Cowen, allowing the company to sell shares up to a specified amount with TD Cowen receiving up to 3.0% commission on proceeds.
Feb 26
Data updated apr 25, 2026 6:18pm
· Source: massive.com